Company intelligence / Profile preview

Stealth Investment Firm

Camana Bay, Cayman Islandsvox.com ↗

Ownership: Private
Development stage: Other

Overview

Stealth BioTherapeutics has advanced its lead candidate elamipretide into multiple late-stage clinical trials for rare genetic mitochondrial disorders and common age-related diseases. Elamipretide has reached phase 3 in Barth syndrome and replisome myopathies; phase 2/3 in Duchenne cardiomyopathy; phase 2a in Friedreich's ataxia; phase 2 in dry AMD and hereditary optic neuropathy. Other pipeline assets include SBT‐20 for metabolic/renal/neurodegenerative indications and SBT‐272/SBT-550 for rare neurological conditions.

Therapeutic areas: CardiovascularOphthalmologyRare DiseasesNeurology
Modalities: Small moleculePeptide
Industry: Biotech

Beyond the preview

Go deeper on Stealth Investment Firm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stealth Investment Firm.

Explore the full profile